We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Nuformix Plc | LSE:NFX | London | Ordinary Share | GB00BYW79Y38 | ORD 0.1P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.005 | -2.70% | 0.18 | 0.18 | 0.22 | 0.18 | 0.18 | 0.18 | 112,466 | 08:10:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 0 | -859k | -0.0012 | -1.50 | 1.34M |
From Apr 2019 to Apr 2024
TIDMNFX
RNS Number : 1048Y
Nuformix PLC
01 December 2017
Nuformix plc
("Nuformix" or "the Company")
Appointment of Broker
Nuformix, the pharmaceutical development company using cocrystal technology to unlock the therapeutic potential of approved small molecule drugs, is pleased to announce the appointment of Beaufort Securities Limited as the Company's broker.
Follow Nuformix on Vox Markets: follow at www.voxmarkets.co.uk/company/NFX
and www.nuformix.com
ENDS
Enquiries:
Nuformix plc Dan Gooding, Chief Executive Officer +44 (0)1223 423667 Beaufort Securities Limited (Joint Broker) +44 (0)20 7382 Jon Belliss 8300 Gable Communications Ltd John Bick / Justine +44 (0)20 7193 James 7463
About Nuformix plc www.nuformix.com
Nuformix is a pharmaceutical development company using cocrystal technology to unlock the therapeutic potential of approved small molecule drugs. Nuformix' risk-mitigated development strategy has resulted in a pipeline of discoveries through which it has developed and patented novel cocrystal forms of approved small molecules.
Nuformix has created an IP portfolio containing a range of granted patents covering cocrystal forms of five small molecule drugs. Nuformix is targeting high-value unmet needs with its lead programmes in oncology supportive care: NXP001 and fibrosis: NXP002.
Nuformix was established in Cambridge in 2008 and has invested into pharmaceutical cocrystal R&D, establishing world-class capability and know-how in cocrystal discovery and development, yielding multiple product opportunities. Nuformix plc shares are traded on the London Stock Exchange's Official List under the ticker: NFX.L.
This information is provided by RNS
The company news service from the London Stock Exchange
END
APPFSWSWFFWSEEE
(END) Dow Jones Newswires
December 01, 2017 02:30 ET (07:30 GMT)
1 Year Nuformix Chart |
1 Month Nuformix Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
